The short version of AEDG fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Calculated from the four residues with three water losses |
| Molecular mass | About 390.35 g/mol | Monoisotopic mass near 390.14, used for mass-spectrometric identification |
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG; no disulfide bonds or modified residues |
| Appearance | White to off-white solid | Supplied as a dried powder |
| Isoelectric point | Around 4 | Estimated from aspartate and glutamate side-chain pKa values |
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
=== Glucose metabolism === PLP is a required coenzyme of glycogen phosphorylase, the enzyme necessary for glycogenolysis. Glycogen serves as a carbohydrate storage molecule, primarily found in muscle, liver and brain. Its breakdown frees up glucose for energy. PLP also catalyzes transamination reactions that are essential for providing amino acids as a substrate for gluconeogenesis, the biosynthesis of glucose.
NHK, JVC and Ikegami Tsushinki researchers built an early UHDTV prototype, Super Hi‑Vision, which they demonstrated in January 2003. They used an array of 16 HDTV recorders with a total capacity of almost 3.5 TB that could capture up to 18 minutes of test footage. The camera itself was built with four 2.5-inch (64 mm) CCD image sensors, each with a resolution of 3840 × 2048 (4K resolution). Using two CCDs for green and one each for red and blue, they then used a spatial pixel offset method to bring it to 7680 × 4320 (8K resolution). Subsequently, NHK built an improved and more compact system using CMOS image sensor technology and the CMOS image sensor system was demonstrated at Expo 2005, Aichi, Japan, the NAB 2006 and NAB 2007 conferences, Las Vegas, at IBC 2006 and IBC 2008, Amsterdam, Netherlands, and CES 2009. A review of the NAB 2006 demo was published in a broadcast engineering e-newsletter. Individuals at NHK and elsewhere projected that the timeframe for UHDTV to be available in domestic homes varied between 2015 and 2020 but Japan was to get it in the 2016 time frame.
==== Delirium ==== A systematic review, published in 2014, concluded "ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo." A 2022 systematic review and meta-analysis found that the combination of ramelteon and the orexin receptor antagonist suvorexant may reduce the incidence of delirium in adults hospitalized patients whereas suvorexant alone was ineffective.
== Ecology == It is ectomycorrhizally associated with several tree species and is symbiotic with them. In Europe, these include hardwood and, less frequently, conifer species. It appears most commonly under oaks, but also under beeches, chestnuts, horse-chestnuts, birches, filberts, hornbeams, pines, and spruces. In other areas, A. phalloides may also be associated with these trees or with only some species. In coastal California, for example, A. phalloides is associated with coast live oak. In countries where it has been introduced, it has been restricted to those exotic trees with which it would associate in its natural range. There is, however, evidence of A. phalloides associating with hemlock and with genera of the Myrtaceae: Eucalyptus in Tanzania and Algeria, and Leptospermum and Kunzea in New Zealand, suggesting that the species may have invasive potential. It may have also been anthropogenically introduced to the island of Cyprus, where it has been documented to fruit within Corylus avellana plantations. This species has once been recorded as food of the pleasing fungus beetle Rotitma sanguinipennis; no other such observation was known as of 1999, and the record is more likely a mix-up with the related Tritoma mimetica, which can indeed be found on Amanita species. It has also been found with adults of the related beetle T.b.biguttata, but it does not seem to be a regular food source for them.
Sources: en.wikipedia.org
The 1993 film Jurassic Park (based on the 1990 Michael Crichton novel of the same name) features dinosaurs that were genetically altered so that they could not produce the amino acid lysine. This was known as the "lysine contingency" and was supposed to prevent the cloned dinosaurs from surviving outside the park, forcing them to be dependent on lysine supplements provided by the park's veterinary staff. In reality, no animals are capable of producing lysine (it is an essential amino acid). Autotroph Bradytroph "Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde transport by the J-domain protein RME-8" - The EMBO Journal "Pleiotropic effects of purine auxotrophy inRhizobium meliloti on cell surface molecules" - Springerlink "Auxotrophy and Organic Compounds in the Nutrition of Marine Phytoplankton"
Uranium (92U) is a naturally occurring radioactive element (radioelement) with no stable isotopes. It has two primordial isotopes, uranium-238 and uranium-235, that have long half-lives and are found in appreciable quantity in Earth's crust. The decay product uranium-234 is also found. Other isotopes such as uranium-233 have been produced in breeder reactors. In addition to isotopes found in nature or nuclear reactors, many isotopes with far shorter half-lives have been produced, ranging from 214U to 242U (except for 220U). The standard atomic weight of natural uranium is 238.02891(3). Natural uranium consists of three main isotopes, 238U (99.2739–99.2752% natural abundance), 235U (0.7198–0.7202%), and 234U (0.0050–0.0059%). All three isotopes are radioactive (i.e., they are radioisotopes), and the most abundant and stable is uranium-238, with a half-life of 4.463×109 years (about the age of the Earth). Uranium-238 is an alpha emitter, decaying through the 18-member uranium series into lead-206. The decay series of uranium-235 (historically called actino-uranium) has 15 members and ends in lead-207. The constant rates of decay in these series makes comparison of the ratios of parent-to-daughter elements useful in radiometric dating. Uranium-233 is made from thorium-232 by neutron bombardment.
The development of insulin therapy has progressed significantly since the early 20th century, starting with animal-derived insulins. In 1922, Frederick Banting and Charles Best successfully used bovine insulin extract to treat humans for the first time. This breakthrough led to the commercial production of bovine insulin in 1923 by Eli Lilly and Company. That same year, Hans Christian Hagedorn founded the Nordisk Insulinlaboratorium in Denmark, which later became Novo Nordisk. In 1926, Nordisk received a Danish charter to produce insulin as a non-profit entity. In 1936, Canadian researchers D.M. Scott and A.M. Fisher developed a zinc insulin mixture, which was licensed to Novo. During this time, Hagedorn discovered that adding protamine to insulin could prolong its action, which led to the development of Neutral Protamine Hagedorn (NPH) insulin in 1946. NPH insulin was marketed by Nordisk in 1950. By 1953, Novo also developed Lente insulin by adding zinc to porcine and bovine insulins, resulting in a longer-acting form. A significant advancement in insulin production occurred in 1978 when Genentech developed the biosynthesis of recombinant human insulin using Escherichia coli bacteria and recombinant DNA technology. This allowed for the production of insulin identical to that produced by the human pancreas. In 1981, Novo Nordisk chemically and enzymatically converted porcine insulin into human insulin. Genentech's synthetic human insulin, produced in partnership with Eli Lilly, was approved by the U.S. Food and Drug Administration in 1982.
And you do not set 2,000 tanks and 20,000 men in motion within 48 hours." On 31 August 2008, Matthew Bryza stated at Bled Strategic Forum in Slovenia that the United States had actively been working to prevent Georgia from responding to South Ossetian attacks. In August 2008, Vadim Kozaev, employee of Ministry of Internal Affairs of North Ossetia–Alania, and his brother Vladislav Kozaev, hero of Abkhazia and South Ossetia, alleged that Eduard Kokoity, the president of South Ossetia, knew in advance that the war was coming and fled Tskhinvali.
In a broad way, it usually includes a test of ruggedness among inter-collaborators, or a test of robustness within an organization However, the U.S. Food and Drug Administration (FDA) has specifically defined it for its administration, as "System suitability testing is an integral part of many analytical procedures. The tests are based on the concept that the equipment, electronics, analytical operations and samples to be analyzed constitute an integral system that can be evaluated as such. System suitability test parameters to be established for a particular procedure depend on the type of procedure being validated". In some cases of analytical chemistry, a system suitability test could be rather a method specific than universal. Such examples are chromatographic analysis, which is usually media (column, paper or mobile solvent) sensitive However to the date of this writing, this kind of approaches are limited to some of pharmaceutical compendial methods, by which the detecting of impurities, or the quality of the intest analyzed are critical (i.e., life and death). This is probably largely due to:
Sources: en.wikipedia.org
No. Epithalamin is a peptide-containing extract of bovine pineal glands, while epitalon is a single synthetic tetrapeptide. The extract contains many peptides and other tissue components, so its composition varies between batches in ways that a synthesised sequence does not.
It is not recognised as an endogenous peptide hormone. The four-residue sequence can appear inside larger proteins and in digestive fragments of dietary protein, but no dedicated pathway producing it as a signalling molecule has been identified.
Several cell-culture reports describe increased telomerase activity after treatment, measured by enzyme assays or by transcript levels. Results differ between cell types and laboratories, and measured telomere lengthening has been reported in some studies but not in others, which leaves the physiological relevance open.
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.